Omeros (OMER) said Friday that clinical trial site activation for enrollment is underway for its phase 3 program evaluating zaltenibart as a possible treatment for paroxysmal nocturnal hemoglobinuria.
A total of 120 clinical sites across 30 countries have been chosen for participation in the zaltenibart phase 3 program, the company said, adding that data needed for submission of the biologics licensing application remains on track for Q4 of 2026
Omeros shares were 1.2% higher in recent trading.
Price: 9.21, Change: +0.11, Percent Change: +1.21
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.